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Purpose: After radiation therapy for painful bone metastases, up to 44% of patients report a pain flare (PF). Our study
compared 2 dose schedules of dexamethasone versus placebo to prevent PF.
Methods and Materials: This double-blind, randomized, placebo-controlled trial allocated patients with painful bone metas-
tases from solid tumors randomly to receive 8 mg dexamethasone before radiation therapy followed by 3 daily doses (group
A), 8 mg dexamethasone followed by 3 doses of placebo (group B), or 4 doses of placebo (group C). Patients reported worst
pain scores, study medication side effects, and opioid intake before treatment and thereafter daily for 14 days and on day 28.
PF was defined as at least a 2-point increase on a 0 to 10 pain scale with no decrease in opioid intake or a 25% or greater
increase in opioid intake with no decrease in pain score, followed by a return to baseline or lower. The primary analysis was
by intention to treat with patients who had missing data classified as having a PF.
Results: From January 2012 to April 2016, 295 patients were randomized. PF incidence was 38% for group A, 27% for group
B, and 39% for group C (PZ .07). Although patients in group B had the lowest PF incidence, a relatively high percentage did
not return to baseline pain levels, indicating pain progression. The mean duration of PF was 2.1 days for group A, 4.5 days for
group B, and 3.3 days for group C (P Z .0567). Dexamethasone postponed PF occurrence; in group A 52% occurred on days
2 to 5 versus 73% in group B and 99% in group C (P Z .02). Patients in group A reported lower mean pain scores on days 2
to 5 than those in group B or C (P < .001). Side effects were similar.
Conclusions: There was insufficient evidence that dexamethasone reduced the incidence of radiation-induced PF. However,
dexamethasone postponed the occurrence of PF and led to lower mean pain scores on days 2 to 5.  2020 Elsevier Inc. All
rights reserved.
Introduction
For patients with advanced cancer and painful bone metas-
tases, radiation therapy is an effective palliative treatment,
with about 62% responding within 3 to 4 weeks after treat-
ment.1 No differences in pain response have been found be-
tween either a single fraction of 8 Gy or multiple fractions
with higher total doses. Some patients experience a transient
increase of pain shortly after radiation therapy, the so-called
pain flare (PF), which has considerable detrimental effects
on quality of life.2 A recent review of prospective studies
reported PF percentages ranging from 2% to 44%.3
Administration of anti-inflammatory drugs such as dexa-
methasone might have a direct beneficial analgesic effect on
pain and prevent the occurrence of PF. In 2015, the Canadian
NCIC SC 23 study in 298 patients showed that 5 daily 8-mg
doses of dexamethasone significantly reduced the incidence
of PF after a single fraction of 8 Gy from 35% to 26% (P Z
.05).4 In The Netherlands, we performed a similar random-
ized study, the Dutch DEXA study, investigating the effec-
tiveness and toxicity of 2 dose schedules of dexamethasone to
prevent the incidence of PF after short schedule radiation
therapy (1  8 Gy or 20-24 Gy in 5-6 fractions) for painful
bone metastases, compared with placebo.
Methods and Materials
Study design
Our study was a randomized, double-blind, placebo-
controlled, 3-armed trial in which patients were entered
from 12 of the 21 Dutch radiation therapy institutes.5
Eligible patients were aged 18 years or older, with un-
complicated painful bone metastases (ie, no actual or
impending fracture and no neurologic symptoms caused by
nerve root or spinal cord compression) from solid tumors.
Pain intensity was between 2 and 8 on a numeric rating
scale from 0 to 10, with no immediately expected changes
in the analgesic regimen, as determined by the treating
physician. Patients could be scheduled for 1  8 Gy or 20
to 24 Gy in 5 to 6 fractions. Patients were excluded when
multiple painful bony sites were to be irradiated, the same
bony site was treated before with radiation therapy, the
patients were currently or recently (<1 week before
randomization) using steroids or expected to use steroids
within 2 weeks after start of radiation therapy, they had a
life expectancy <8 weeks, or they had a Karnofsky Per-
formance Status Scale score of 40. All participating
centers received approval from local medical ethics boards,
and written informed consent was obtained from all
participating patients. This study is registered with
ClinicalTrials.gov, number NCT01669499.
Randomization
Patients were randomly assigned (1:1:1) to receive orally 4
 8 mg dexamethasone (group A), one 8-mg dose of
dexamethasone followed by 3 placebo (group B), or 4
placebo (group C). Randomization was performed centrally
using a computer-made randomization list and was strati-
fied by radiation therapy schedule (single or multiple
fractions) and by participating center. The outcome of the
randomization was blinded for the treating radiation
oncologist, patient, principal investigators, and study
statistician.
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Procedures
The study medication was manufactured and supplied
centrally by the Department of Pharmacy of the University
Medical Center Utrecht. The medication was provided in
numbered medication boxes containing 4 identical cap-
sules. Patients were instructed to take the first capsule at
least 1 hour before the start of radiation therapy (day 0) and
then every day for 3 days (days 1-3), preferably with
breakfast. Treatment of any pain after radiation therapy was
at the discretion of the treating physician. In patients with
severe pain not responding to analgesic increase, treatment
with open-label dexamethasone was allowed.
Patients were given a diary to report pain and quality of
life and instructed to describe pain experienced at the
irradiated bony localization only. For pain, the brief pain
inventory was used with pain scores ranging from 0 (no
pain) to 10 (worst imaginable pain).6 Patients reported their
worst daily pain score at baseline before radiation therapy
(day 0) and then once daily for 14 days (days 1-14) and on
day 28. They also recorded their daily pain medication
intake. Furthermore, they answered 2 additional questions
on restlessness and appetite to investigate possible side
effects of the study medication, scored from 1 (not at all) to
4 (very much). For quality of life, patients completed the
EORTC QLQ-C15-PAL questionnaire and the EORTC
QLQ-BM22 bone metastases module at baseline (day 0)
and on days 7, 14, and 28.7,8
Outcomes
The primary outcome measure was the occurrence of PF,
defined by a 2-point increase in the worst pain score after
radiation therapy compared with baseline without a
decrease in analgesic intake or a 25% increase in analgesic
intake without a decrease in worst pain score.9 We
considered a PF early in onset if it started on days 2 to 5
and late if it started on days 6 to 14. PF was distinguished
from pain progression by requiring the worst pain score
and/or analgesic intake to return to baseline levels before or
on day 14. If this was not the case, pain was classified as
pain progression. Secondary outcomes were pain scores on
days 1 to 14 and 28, side effects of the study medication,
and quality of life.
Statistical analysis
The study was designed as a superiority study assuming a
reduction of 50% (from 40% to 20%) of the occurrence of
PF by administering 4  8 mg dexamethasone compared
with placebo.10 We expected a dropout of 20% and 2 years
to complete the trial. Assuming a 90% power (beta Z 0.1)
and 2-sided alpha of 5%, a total of 411 patients was
necessary. Because of slow accrual, the protocol was
amended after 3 years to change the beta to 0.2. A sample
size of 294 patients (98 per group) was then required.
After publication of the NCIC CTG SC 23 study, we
decided to perform intention-to-treat and sensitivity ana-
lyses in line with the NCIC CTG SC.23 analyses to be able
to compare the results.4 Patients who had received at least 1
fraction of radiation therapy were evaluable irrespective of
intake of study medication. For the intention-to-treat anal-
ysis, we assumed that patients who were not assessable
owing to missing data had experienced a PF. We also per-
formed a sensitivity analysis assuming that patients with
missing pain scores did not have a PF.
To study the influence of missing data on outcome, we
calculated PF incidence leaving out patients with missing
data. We used the Fisher exact test for comparison of the
percentages of occurrence of PF and the timing of PF
among the 3 groups. Differences in duration of PF were
assessed with a 1-way analysis of variance on the log-
transformed durations. To check for influence of changes in
opioid intake, we calculated median cumulative oral
morphine equivalence doses during the first 14 days and
interquartile ranges (IQRs) and compared those using
analysis of variance. To check for influence of fractionation
on PF incidence, we compared the incidence of PF for the
patients receiving a single fraction of 8 Gy versus those
receiving 20 Gy in 5 fractions using the Fisher exact test.
Changes over time in mean pain scores, study medication
side effects, and quality of life scores for all groups were
analyzed using linear mixed models with fixed effects for
treatment group, time (using B-splines to account for
nonlinear trends over time), and their interaction, as well as
a random intercept and random slope for time per subject.
The treatment  time interaction was tested using the
likelihood ratio test. In case of significant interactions, post
hoc tests were used to compare the treatment groups on day
1 (second day of intake study medication), day 4 (first day
without study medication), and day 9 (any effect of study
medication washed out). All analyses were done with SAS,
version 9.4. All P values were 2-sided.
Results
From January 2012 to April 2016, 295 patients were ran-
domized (Fig. 1). Patient characteristics are described in
Table 1. In patients using pain medication, the use of opi-
oids at randomization was 45% (38 patients) in group A,
56% (41 patients) in group B, and 49% (41 patients) in
group C. The number of patients not assessable for PF
incidence within the first 14 days was 20 in group A, 17 in
group B, and 27 in group C (Fig. 1). In total, 38 patients
had missing data.
In the intention-to-treat analysis, 103 patients experi-
enced a PF within the first 14 days: 38 (38%) in group A,
26 (27%) in group B, and 39 (39%) in group C (P Z .07)
(Table 2). The percentages of patients with no PF and no
pain progression were 48% in group A, 50% in group B,
and 37% in group C. When patients with missing data (nZ
38) were censored, the percentages of patients experiencing
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a PF within 14 days were comparable: 38.5% in group A,
23% in group B, and 38.5% in group C (P Z .07).
In the sensitivity analysis, assuming that patients with
missing pain scores did not have a PF, 65 patients experi-
enced a PF within the first 14 days: 25 patients (25%) in
group A, 15 patients (16%) in group B, and 25 patients
(25%) in group C (P Z .09). The percentages of patients
with no PF and no pain progression were 61% in both
group A and group B and 51% in group C. In group A, 52%
of the PFs occurred on days 2 to 5, compared with 73% in
group B and 88% in group C (P Z .02). The mean duration
of the PF was 2.1 days in group A, 4.5 days in group B, and
3.3 days in group C (P Z .0567).
Figure 2 depicts the course of pain during the 14 days
after the start of radiation therapy and at day 28, showing
statistically significant differences in the course of pain for
the 3 groups (P < .001). On day 1, patients in groups A and
B had significantly lower scores than those in group C (P
Z .0107 and .0244, respectively). On day 4, patients in
group A had a lower mean score than those in groups B and
C (P Z .0121 and .0217, respectively). No statistically
significant differences were found among the groups on
day 9.
The median cumulative oral morphine equivalence dose
was 317 mg (IQR, 125-919) in group A, 421 mg (IQR, 127-
1039) in group B, and 374 mg (IQR, 205-954) in group C
during the 14 days after radiation therapy. The difference in
oral morphine equivalence doses among the 3 treatment
groups was not significant (P Z .28).
Of the 233 patients receiving a single fraction of 8 Gy,
36% experienced a PF and 46% no PF in the intention-to-
treat analysis, versus 27% PF and 51% no PF among 41
patients receiving 20 Gy in 5 fractions (P Z .52). In the
sensitivity analysis, these percentages were 23% with a PF
and 59% with no PF after single-fraction 8 Gy versus 22%
PF and 56% no PF after 20 Gy (P Z .72).
During the study period, 12 serious adverse events were
reported (9 hospital admittances and death in 3 patients),
mostly caused by deteriorating condition. All were deter-
mined to be unrelated to the study medication.
The compliance rates for the EORTC-QLQ-C15 PAL
and BM22 quality of life questionnaires were similar
among the 3 arms, varying from 74% to 88%. Except for
pain and functional interference, no clear changes over time
were observed (Figs. E3 and E4). Mean pain scores
(EORTC QLQ-C15 PAL and BM22) decreased by about 10
to 15 points, and median scores for functional interference
(EORTC QLQ-BM22) improved by about 10 points. The
median scores for overall quality of life and physical
functioning (C15 PAL) varied, approximately 60 and 80,
respectively, and remained stable. Nausea score (EORTC
QLQ-C15 PAL) varied, approximately 10, and remained
stable. There were no statistically significant differences for
most of the quality of life scales and items.
Regarding the additional questions on medication side
effects, patients in group A experienced significantly more
restlessness on day 5 than did patients in group C (PZ .02)
(Fig. E5). The difference in appetite between groups A and
B was significant on day 5 (P Z .004). All effect sizes,
however, were small.
Discussion
In our randomized study of 295 patients with painful bone
metastases, we did not find a statistically significant effect
of 2 dose schedules of dexamethasone on the incidence of
PF after palliative radiation therapy or on the duration of
PF. In the intention-to-treat analysis, a PF occurred in 38%
295 enrolled
295 randomized
100 assigned group A; 4x dexa 95 assigned group B; 1x dexa,
3x placebo
100 assigned group C; 4x placebo
20 not assessable for pain flare
1 not eligible (steroid use)
1 died
2 declined further study
participation

















1 died5 withdrew consent for data
submission
17 not assessable for pain flare 27 not assessable for pain flare
2 not eligible (steroid use)
3 declined further study
participation
7 withdrew consent for data
submission
14 missing data
73 assessable for pain flare
100 included in ITT analysis95 included in ITT analysis100 included in ITT analysis
80 assessable for pain flare 78 assessable for pain flare
Fig. 1. Trial profile. Missing data refer to patients without a complete 14-day pain diary.
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Table 1 Patient characteristics by randomization group
Group A
Dexamethasone









n %* n % n %
Sex
Male 61 62 51 54 61 62
Female 38 38 43 46 38 38
Missing 1 1 1
Age
Mean, y 67 65 68
Range, y 30-84 40-91 44-85
Missing, n 1 1 1
Karnofsky Performance Status Scale score
90-100 29 30 27 29 27 28
70-80 52 53 51 55 54 56
40-60 17 17 15 16 16 17
Missing 2 2 3
Primary tumor
Prostate 30 30 24 25 29 30
Breast 27 27 27 29 22 23
Lung 17 17 21 22 24 25
Other 25 25 22 23 21 22
Missing 1 1 4
Current other treatments
None 30 32 35 41 42 46
Chemotherapy 13 14 9 11 10 11
Antihormonal therapy 38 40 27 31 31 34
Bisphosphonates 3 3 3 4 0 0
Combination 11 12 12 14 9 10
Missing 5 9 8
Use of pain medication at randomization
No 14 14 21 22 14 14
Yesy 85 86 73 78 83 86
Missing 1 1 3
Worst pain score at randomization
Mean 6 6 5
7-8 47 48 44 47 39 40
5-6 25 25 30 32 27 27
2-4 26 27 19 20 32 33
Missing 2 2 2
No. of fractions
1  8 Gy 75 77 78 83 80 81
5  4 Gy 16 17 13 14 12 12
6  4 Gy 1 1 1 1 0 0
Otherz 5 5 2 2 6 6
Missing 3 1 1
Previous radiation therapy on other
bone metastases
Yes 11 16 15 21 12 17
No 59 84 55 79 57 83
Missing 30 25 31
* Due to rounding of decimals, totals can add up to less or greater than 100%.
y Intake of any pain medication, paracetamol, neuropathic pain medication, opioid, or nonsteroidal anti-inflammatory pain medication reported at
randomization.
z Five, 2, and 6 patients in groups A, B, and C, respectively, received other schedules, namely 2  8 Gy, 3  4 Gy, or 4  4 Gy.
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of patients receiving 4 daily doses of 8 mg dexamethasone
and 39% of patients receiving 4 daily doses of placebo.
Surprisingly, the lowest PF incidence (27%) was observed
in patients receiving 1 dose of dexamethasone 8 mg fol-
lowed by 3 daily doses of placebo. However, these differ-
ences were not statistically significant (PZ .07). If patients
with missing data were assumed not to have had a PF
(sensitivity analysis), there were still no significant differ-
ences among the 3 groups.
A recent review including 7 prospective studies on PF
incidence (using comparable definitions of PF) after
external beam radiation therapy reported PF percentages
ranging from 2% to 44% without intake of dexametha-
sone.3 A phase 2 study included in the review reported a
24% incidence of PF in 23 patients receiving 8 mg dexa-
methasone orally before a single dose (8 Gy) of radiation
therapy,10 seemingly lower than the 41% incidence found
in a previous study in 44 patients not receiving dexameth-
asone.9 Another nonrandomized study in the review re-
ported a PF within 10 days in 22% of 41 patients receiving
a single 8-Gy fraction in combination with 8 mg dexa-
methasone orally before radiation therapy and for 3
consecutive days after treatment.11
The lowest percentages were reported in a double-blind
randomized study in 120 patients with vertebral metastases
receiving either a 24-hour infusion of 5 mg/kg methyl-
prednisolone or placebo before radiation therapy.12 A sig-
nificant effect on incidence (6.6% vs 20%) and mean
duration (1.25 vs 3.75 days) of PF was seen in patients
receiving methylprednisolone.
In the previously mentioned NCIC SC23 trial, 298 pa-
tients with painful bone metastases from solid tumors
receiving a single 8-Gy dose were randomized to receive
either 8 mg dexamethasone or placebo orally before radi-
ation therapy and then 4 days thereafter.1 In the intention-
to-treat analysis, assuming that patients with missing data
(n Z 22) had had a PF, a PF within the first 10 days
occurred in 26% of patients receiving 5 doses of dexa-
methasone versus 35% of patients receiving placebo (1-
sided P Z .05). In the sensitivity analysis, assuming that
patients with missing data had had no PF, the percentages
were 18% and 29%, respectively (P Z .01). The median
duration of the PF was 3 days in the dexamethasone group
and 2 days in the placebo group. Differences in mean pain
scores per day were not reported.
For patients receiving one 8-mg dose of dexametha-
sone followed by placebo (group B) or only placebo
(group C), our results are comparable to the study arms in
the NCIC trial4 (Table 3). The lack of statistical signifi-
cance for the difference between these 2 groups in our
study may be explained by the relatively low power of our
study, which we were forced to lower when accrual














Not assessabley 7 (7%) 6 (6%) 13 (13%) .07
No pain flare and no pain progression 48 (48%) 47 (50%) 37 (37%)
Pain progression 7 (7%) 16 (17%) 11 (11%)
Pain flare 38 (38%) 26 (27%) 39 (39%)
Sensitivity analysis
Not assessable 7 (7%) 6 (6%) 13 (13%) .09
No pain flare and no pain progression 61 (61%) 58 (61%) 51 (51%)
Pain progression 7 (7%) 16 (17%) 11 (11%)
Pain flare 25 (25%) 15 (16%) 25 (25%)
* Data on pain scores during follow-up were missing in 13 patients in group A, 11 patients in group B, and 14 patients in group C. In the intention-to-
treat analysis these patients were considered to have experienced a pain flare; in the sensitivity analysis these patients were considered to have expe-
rienced no pain flare.
y Patients were considered not assessable for both analyses only if they were not eligible due to steroid use, died, declined further participation, or





















PatArm 4x placebo 1x dexa, 3x placebo 4x dexa
Fig. 2. Course of pain. Mean worst pain scores during the
study period. Of note, day 0 is the first day with intake of
medication and start of the radiation therapy. The first 14
days are daily measurements (days 0-14), with a last
measurement on day 28.
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remained low. However, the unexpected results in group A
receiving 4 doses of 8 mg dexamethasone are difficult to
explain. In both the intention-to-treat and sensitivity an-
alyses, the occurrence of PF in this group is almost
identical to that of the placebo group C and very different
from the results of the NCIC trial. There were no
remarkable differences among patients in groups A, B, or
C that might explain the difference in incidence of PF. A
PF occurred much more often (38% of group A patients)
than in the study by Hird et al,11 who used the same
dexamethasone dosages and found an incidence of only
22%, comparable to the NCIC outcome (26%). We have
no good explanation regarding why in our study a single
dose of 8 mg seemed more effective than 4 daily doses of
8 mg dexamethasone in the prevention of PF. A remark-
able finding was the relatively high percentage (17%) of
patients in group B with pain progression. In contrast, in
groups A (4  dexamethasone) and C (4  placebo), pain
progression was observed in only 7% and 11% of patients,
respectively.
In this study, both dexamethasone schedules signifi-
cantly postponed the occurrence of PF compared with
placebo. This effect was also observed in NCIC SC23. In
addition, treatment with dexamethasone resulted in signif-
icantly lower pain scores on day 1 (groups A and B) and
day 4 (group A only) compared with placebo, implying a
direct analgesic effect. In NCIC SC23 the authors reported
a mean reduction in pain score for days 0 to 5 favoring the
dexamethasone group (e1.79 vs e1.09, P Z .01). A recent
review on the effect of corticosteroids on cancer pain also
reported an analgesic effect, although moderate.13
Treatment with dexamethasone was well tolerated in
this study. Patients in group A reported a small, but sig-
nificant, increase in appetite, which may be a welcome
side effect in advanced cancer. They also reported a
higher level of restlessness on day 5, compared with
placebo. The NCIC trial described improvement in scores
for nausea, functional interference, and appetite. In this
study, the opposite was seen: Nausea was lower in pa-
tients using only placebo. Except for pain and functional
impairment, there were no significant changes in the
quality of life subscales and items over time in any of the
arms.
The NCIC trial reported a number needed to treat to
prevent a PF of 11 for the intention-to-treat and 9 for the
sensitivity analysis.4 The researchers concluded that
because of the additional improvement in quality of life
items, the prophylactic use of dexamethasone should be
adopted as standard of care for patients receiving pallia-
tive radiation therapy for painful bone metastases. If our
results are seen from the perspective of not having a PF or
pain progression, a trend for a beneficial effect of dexa-
methasone becomes visible: 48% had no PF or pain pro-
gression in group A and 50% in group B versus 37% in
group C in the intention-to-treat analysis. In the sensitivity
analysis, these percentages were 61% in groups A and B
versus 51% in group C. To prevent PF or pain progression,
we estimate a number needed to treat of 9 based on the
intention-to-treat analysis and 10 based on the sensitivity
analysis.
Although we allowed patients to undergo either an 8 Gy
single-fraction or multiple-fraction radiation therapy, there
Table 3 Comparison of the 2 randomized pain flare trials on dexamethasone; NCIC CTG SC 23 and Dutch DEXA study.


















5  8 mg
26% 18% 3 d Dexamethasone
4  8 mg
(group A)
38% 25% 1.5 d
Dexamethasone
1  8 mg
Placebo
3 (group B)
27% 16% 4.5 d
Placebo
5
35% 29% 2 d Placebo
4 (group C)
39% 25% 3.3 d
Study design and criteria
Superiority study
One-sided alpha 0.05, power 90%
Intake of NSAIDs not allowed
Total dose dexamethasone 40 mg in study arm
10-d follow-up daily pain scores and on day 42
EORTC PAL15 and BM22 QoL questionnaires on days 0, 10,
and 42
Study design and criteria
Superiority study
Two-sided alpha 0.05, power 80%
Intake of NSAIDs allowed
Total dose dexamethasone maximum 32 mg in group A
14-d follow-up daily pain scores and on day 28
EORTC PAL15 and BM22 QoL questionnaires on days 0, 7, 14,
and 28
Abbreviation: NSAIDs Z nonsteroidal anti-inflammatory drugs.
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was no difference in the incidence of PF among the 3
groups. Hird et al reported similar PF incidences after 8-Gy
single-fraction or 20 Gy in 5 fractions in 111 patients: 39%
and 41%, respectively.14
The main limitations of this study are its lack of sta-
tistical power and the considerable number of missing pain
scores. During the study period we adjusted the power
from 90% to 80%, owing to slow accrual of patients. This
relatively low power, together with the unexpected and
unexplained high incidence of PF in group A, may explain
the lack of statistical difference for the occurrence of PF in
the first 2 weeks after treatment. Sixty-four patients (22%)
were not assessable, 38 because of missing pain scores in
the pain diary and 26 mostly owing to early death,
declining further study participation, or withdrawal of
consent; this reflects both the very vulnerable patient
population and problems inherent to studies using repeated
questionnaires. It is unlikely that dropout was influenced
by the allocated treatment. The lack of a statistical differ-
ence between the groups may also be a false-negative
finding.
A recent debate on the use of dexamethasone to prevent
PF concluded that consensus for routine use could not be
achieved, and the choice to use dexamethasone prophy-
lactically is a shared decision between radiation oncologists
and patients.15 Factors including symptom burden, comor-
bidities, performance status, quality of life, and radiation
dose and fractionation should be considered on an indi-
vidual level.
Conclusions
Prophylactic intake of dexamethasone had no clear effect
on reducing PF incidence after radiation therapy for
painful bone metastases, although an immediate effect
on pain was observed. Repeat studies should be
performed to solve the discrepancy between the results of
this study and previous results. In addition to prevention
of PF, the mechanisms of direct pain reduction in
combination with palliative radiation therapy should be a
topic of further dose-effect studies, identifying
optimal doses of dexamethasone intake and the optimal
duration.
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